Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


JPMA Reports Overseas Drug Makers Favoring China Over Japan As R&D Base

This article was originally published in PharmAsia News

Executive Summary

A Japan Pharmaceutical Manufacturers Association policy report shows that U.S. and European drug makers prefer China over Japan in establishing research and development bases. The reasons cited by the JPMA report include China's national policy to promote science and technology and its active recruitment of talent and enterprises from overseas. Additionally, China fosters clusters of domestic and foreign researchers and has improved the environment for R&D, such as the Shanghai Zhangjiang Hi-tech Park, where 120 venture companies, CROs and Shanghai Institute of Material Medica are based. The report also criticized Japan's late response to internationalization in R&D. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts